Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 09 Apr 2026 | Maria Pilar Aguar Fernandez Director | Sanofi’s research and development (R&D) strategy in the European context. | — |
| 09 Apr 2026 | Maria Pilar Aguar Fernandez Director | Sanofi’s research and development (R&D) strategy in the European context. | SRC |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 28 Jan 2026 | Vita Jukne Cabinet member | Implication of REACH revision and the upcoming Per- and Polyfluoroalkyl Substances (PFAS) | SRC |
| 28 Jan 2026 | Vita Jukne Cabinet member | Implication of REACH revision and the upcoming Per- and Polyfluoroalkyl Substances (PFAS) | — |
| 05 Dec 2025 | Stéphane Séjourné Executive Vice-President | Industrie pharmaceutique, innovation et souveraineté sanitaire européenne. | SRC |
| 05 Dec 2025 | Stéphane Séjourné Executive Vice-President | Industrie pharmaceutique, innovation et souveraineté sanitaire européenne. | — |
| 28 Oct 2025 | Dorota Denning Cabinet member | Roundtable on Simplification for Pharmaceutical Innovation | SRC |
| 28 Oct 2025 | Dorota Denning Cabinet member | Roundtable on Simplification for Pharmaceutical Innovation | — |
| 10 Sept 2025 | Cecile Billaux Head of Unit | Overview of Sanofi’s actions in global health and on local manufacturing in Africa | — |
| 10 Sept 2025 | Cecile Billaux Head of Unit | Overview of Sanofi’s actions in global health and on local manufacturing in Africa | SRC |
| 05 Sept 2025 | Stéphane Séjourné Executive Vice-President | - Compétitivité des entreprises - Marché intérieur - Protection de la souveraineté et du pouvoir d’achat - Relation US/EU | SRC |
| 05 Sept 2025 | Sacha Halphen Cabinet member | - Compétitivité des entreprises - Marché intérieur - Protection de la souveraineté et du pouvoir d’achat - Relation US/EU | SRC |
| 05 Sept 2025 | Sacha Halphen Cabinet member | - Compétitivité des entreprises - Marché intérieur - Protection de la souveraineté et du pouvoir d’achat - Relation US/EU | — |
| 04 Sept 2025 | Saila Rinne Head of Unit | Virtual Human Twins | SRC |
| 04 Sept 2025 | Rainer Becker Director | Exchange of views on multinational clinical trials in the context of the upcoming Biotech Act | SRC |
| 04 Sept 2025 | Saila Rinne Head of Unit | Virtual Human Twins | — |
| 04 Sept 2025 | Lucilla Sioli Director | Virtual Human Twins | SRC |
| 04 Sept 2025 | Rainer Becker Director | Exchange of views on multinational clinical trials in the context of the upcoming Biotech Act | — |
| 04 Sept 2025 | Lucilla Sioli Director | Virtual Human Twins | — |
| 29 Jul 2025 | Florika Fink-Hooijer Director-General | Health security and innovation across Europe, SANOFI’s relevant activities | — |
| 29 Jul 2025 | Florika Fink-Hooijer Director-General | Health security and innovation across Europe, SANOFI’s relevant activities | SRC |
| 15 Jul 2025 | Marco Marsella Director | The Digital Human. This flagship program leverages AI-driven avatars and advanced health data solutions. | SRC |
| 15 Jul 2025 | Marco Marsella Director | The Digital Human. This flagship program leverages AI-driven avatars and advanced health data solutions. | — |
Mission & Goals
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. We are driven by a unifying purpose and a common ambition. We believe our cutting-edge science and manufacturing, fueled by data and digital technologies, have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. With more than 100,000 people in 100 countries, we chase the miracles of science to improve people’s lives.
EU Legislative Interests
- Revision of the general pharmaceutical legislation - Digital in Healthcare - AI Act - European Health Data Space - Urban wastewater treatment directive - Health Emergency Response Authority - Critical Medicines Act - Biotech Act - Pandemic preparedness - Cross-border health threats - Shortages of medicines - Technical support instrument - MFF - Manufacturing/value-chain of pharmaceuticals/industrial strategy - EU Vaccines policies and vaccine-related activities/prevention - European green deal agenda - EU pharmaceutical strategy - EU Competitiveness and Industrial policy - State aid policy/IPCEI - Economic Security Strategy - EU Research policy / framework program/IHI - Health Technology Assessment Regulation - Pharmaceuticals in the environment - REACH - Trade agreements - Safe Hearts Plan and Cardiovascular Strategy - Self-care Related to above listed topics, senior leaders and experts of Sanofi participate intuitu personae in working groups of the Conseil de Cooperation Economique (CCE), without Sanofi being a member of the CCE.
Communication Activities
Sanofi activities included sponsorship of events in 2025 such as: Sponsorship of the Politico Health Care Summit 2025: https://www.politico.eu/healthcare-summit/#partners
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Professional associations: AFEP (French Association of Private Companies) EFPIA - European Federation of Pharmaceutical Industries and Associations) Vaccines Europe EUCOPE France Industrie MEDEF
Organisation Members
Sanofi's representation towards the EU institutions is led and performed by members of the Corporate Public Affairs function.
Additional Information
Sanofi is a global company with a diversified portfolio of medicines and vaccines covering specialty care, general medicines, immunization and self-care. This declaration includes costs relevant to the Transparency Register that are incurred by Sanofi in and beyond our EU Office, i.e. expenses linked to our business units’ activities that fall within the scope of the register. This includes position papers and articles, background research, events, etc, including costs incurred by intermediary contracts. We have also included the percentage calculation of time spent on activities covered by the Register by employees of the company based outside our EU Office in Brussels.
Connected Legislation